Relmada Therapeutics

RLMD Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-19

Catalyst timeline

NDV-01 readout2026NDV-01 readout, 2026, material
NDV-01 IND filingyear-end 2026NDV-01 IND filing, year-end 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

NDV-01

Small Molecule

Non-Muscle-Invasive Bladder Cancer Phase 2 intravesical Trigone NCT06663137

sepranolone

Small Molecule Target: GABAA receptor alpha-2, GABAA receptor alpha-4, GABA-A receptor alpha-2, GABA-A receptor alpha-4

Prader-Willi Syndrome Preclinical subcutaneous
Tourette Syndrome Phase 2 subcutaneous
Essential Tremor Phase 2

Discontinued (2)

esmethadone — Major Depressive Disorder · Program terminated effective July 7, 2025 following interim futility analysis in Phase 3 Reliance II study
psilocybin — undisclosed · Program terminated effective May 12, 2025.

Biotech Distilled coverage (2)

2026-08-07 UPDATE: Relmada Therapeutics (RLMD) - The Catalyst Just Moved Right
2026-06-23 Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.